List of Excipients in Branded Drug SILVER SULFADIAZINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Liberty Pharmaceuticals Inc	SILVER SULFADIAZINE	silver sulfadiazine	0440-0124	ISOPROPYL MYRISTATE
Liberty Pharmaceuticals Inc	SILVER SULFADIAZINE	silver sulfadiazine	0440-0124	METHYLPARABEN
Liberty Pharmaceuticals Inc	SILVER SULFADIAZINE	silver sulfadiazine	0440-0124	PETROLATUM
Liberty Pharmaceuticals Inc	SILVER SULFADIAZINE	silver sulfadiazine	0440-0124	POLYOXYL 40 STEARATE

Generic Drugs Containing SILVER SULFADIAZINE

Company	Ingredient	NDC	Excipient
Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC	silver sulfadiazine	49999-185	CETYL ALCOHOL
Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC	silver sulfadiazine	49999-185	ISOPROPYL MYRISTATE
Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC	silver sulfadiazine	49999-185	METHYLPARABEN
Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC	silver sulfadiazine	49999-185	PETROLATUM

What are the Most Frequently-Used Excipients in SILVER SULFADIAZINE?

# Of NDCs	Excipient
2	CETYL ALCOHOL
2	ISOPROPYL MYRISTATE
2	METHYLPARABEN
2	PETROLATUM

Silver Sulfadiazine Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Silver sulfadiazine is a mature, generic topical antimicrobial used primarily as a 1% cream for prevention and treatment of wound infection in second- and third-degree burns. Its core active ingredient has limited remaining patent value. Commercial opportunity is concentrated in formulation differentiation, packaging, workflow efficiency, pediatric and outpatient use, and products that reduce residue, staining, application burden, or waste.

The strongest development strategy is usually an improved topical product rather than a conventional silver sulfadiazine generic. Potential platforms include a low-residue cream, hydrogel, foam, sprayable formulation, dressing, unit-dose package, or combination wound-care product. Regulatory classification depends on whether the product remains pharmaceutically equivalent to the reference product or introduces a new dosage form, excipient system, delivery mechanism, or clinical claim.

What is silver sulfadiazine and how is it used?

Silver sulfadiazine is a topical sulfonamide antimicrobial containing silver ions and sulfadiazine. The reference product, Silvadene Cream 1%, is indicated for preventing and treating wound infection in patients with second- and third-degree burns. The product is applied after cleansing and debridement, generally once or twice daily, with reapplication where needed because cream can be removed by wound exudate or patient movement (FDA, 2023a).

Attribute	Current product profile
Active ingredient	Silver sulfadiazine
Strength	1% w/w
Dosage form	Topical cream
Primary indication	Second- and third-degree burns
Administration	Topical application to burn wounds
Regulatory status	FDA-approved prescription drug
Reference brand	Silvadene Cream 1%
Main users	Burn centers, hospitals, emergency departments, outpatient wound clinics
Main commercial competitors	Generic silver sulfadiazine creams, alternative topical antimicrobials, antimicrobial dressings
Principal limitations	Repeated application, cream removal, residue, messiness, potential delayed epithelialization concerns, sulfonamide-related restrictions

Silver sulfadiazine is not a biologic. Biosimilar competition is therefore not relevant. Competitive pressure comes from ANDA-approved generic creams and alternative wound-care products.

What excipients are used in silver sulfadiazine cream?

The reference formulation uses a water-miscible cream base. The labeled inactive ingredients include cetyl alcohol, stearyl alcohol, isopropyl myristate, polysorbate 60, propylene glycol, and purified water (FDA, 2023a).

These excipients perform different technical functions:

Excipient or excipient class	Functional role	Commercial relevance
Cetyl alcohol	Consistency agent, emollient, co-structurant	Controls spreadability and cream body
Stearyl alcohol	Consistency agent and emulsion stabilizer	Supports viscosity and physical stability
Isopropyl myristate	Emollient and oil-phase spreading agent	Improves slip and skin feel
Polysorbate 60	Nonionic emulsifier	Stabilizes the oil-in-water system
Propylene glycol	Humectant, cosolvent, penetration and wetting aid	Supports moisture retention and processability
Purified water	Continuous phase and vehicle	Determines rheology, evaporation, and microbial-control requirements

The formulation is commercially familiar, but the excipient system creates several development constraints. Silver sulfadiazine must remain physically dispersed and chemically stable. The formulation must maintain uniform drug content despite the low water solubility and particulate nature of the active. The product also must tolerate repeated opening, topical contamination, and exposure to wound exudate.

How should an excipient strategy be designed for silver sulfadiazine?

The preferred excipient strategy depends on the commercial objective. A low-cost generic should preserve the reference product’s critical quality attributes. A differentiated product can use excipients to change residence time, delivery, application properties, or packaging.

Strategy for a reference-equivalent generic

A conventional ANDA product should prioritize:

1. Equivalent active concentration and dosage form.
2. Comparable particle-size distribution for micronized silver sulfadiazine.
3. Similar viscosity and spreadability.
4. Comparable pH and emulsion structure.
5. Equivalent or justified drug-release behavior.
6. Container-closure compatibility.
7. Microbiological quality and preservative control.
8. Demonstrated content uniformity across the package.

The lowest-risk excipient approach is to use the established cetyl alcohol, stearyl alcohol, isopropyl myristate, polysorbate 60, propylene glycol, and water system, with manufacturing controls that reproduce the reference product’s physical properties.

A generic manufacturer can still obtain commercial differentiation through tube size, unit-dose packaging, contract manufacturing cost, hospital contracting, and supply reliability. Excipient changes that do not improve the product may add regulatory and technical risk without creating pricing power.

Strategy for a low-residue cream

A lower-residue formulation could reduce the heavy or greasy feel associated with traditional burn creams. The developer would likely adjust:

• Oil-phase content.
• Fatty alcohol concentration.
• Emulsifier level.
• Humectant balance.
• Droplet size.
• Rheology modifiers.
• Wash-off behavior.

The target product would spread quickly, remain on the wound, and remove cleanly during dressing changes. A low-residue claim would require objective comparative testing, including spreadability, residue after application, wash-off, and retention under simulated wound-fluid conditions.

The principal risk is that reducing cream structure can increase phase separation, drug settling, run-off, or dose nonuniformity.

Strategy for a hydrogel or gel system

A hydrogel could offer cooling, lower occlusiveness, and easier application to irregular wounds. Candidate excipient classes include carbomers, cellulose derivatives, poloxamers, hydroxyethylcellulose, and other hydrophilic polymers.

The key development issue is silver sulfadiazine compatibility. The formulation must control:

• Silver ion availability.
• Sulfadiazine solubility and precipitation.
• Polymer interaction with silver.
• Viscosity over shelf life.
• Microbial preservation.
• Drug distribution.
• Wound-fluid dilution.

Some polymers, buffers, chelators, or ionic excipients may bind silver or alter antimicrobial activity. The formulation should therefore be screened for silver complexation, precipitation, discoloration, and changes in antimicrobial performance.

A hydrogel with a new dosage form would generally have a higher regulatory burden than a cream that is pharmaceutically equivalent to the reference product. It may be more suitable for a 505(b)(2) development pathway than a standard ANDA, depending on the proposed claims and product characteristics (FDA, 2019).

Strategy for a foam, spray, or pump product

A foam or pump system could improve application in outpatient settings and reduce direct hand contact. It may support:

• Faster application over large surface areas.
• More consistent coverage.
• Reduced contamination from repeated jar opening.
• Better use in emergency departments and home care.
• Lower product waste.

Aerosol and propellant systems introduce additional requirements, including dose delivery, valve performance, flammability, container pressure, plume characteristics, microbial protection, and extractables and leachables. A non-aerosol pump or metered spray is likely to present fewer safety and manufacturing barriers than a pressurized aerosol.

The main commercial question is whether a spray can deliver a uniform dose to damaged tissue without causing unacceptable pain, cooling, run-off, or inhalation exposure.

What formulations are protected by silver sulfadiazine patents?

The mature silver sulfadiazine cream market has limited practical patent protection around the basic active ingredient and conventional 1% cream. The original product and early formulation rights are historical rather than meaningful barriers to current generic entry.

Potentially protectable subject matter remains in newer delivery systems, including:

• Silver sulfadiazine particle engineering.
• Controlled-release wound dressings.
• Adhesive films.
• Hydrogel matrices.
• Foams and sprays.
• Combination products with other antimicrobials.
• Packaging that controls contamination or dosing.
• Manufacturing methods that improve uniformity or stability.
• Formulations designed for reduced staining or improved epithelialization.

Patentability will depend on whether the claimed excipient combination produces an unexpected technical result. A simple substitution of a known thickener, emulsifier, humectant, or preservative is vulnerable to obviousness challenges unless supported by comparative data.

The strongest formulation patent would connect a defined excipient system to measurable performance, such as superior residence time, reduced silver sulfadiazine degradation, improved release, lower residue, or improved wound compatibility.

When does silver sulfadiazine lose exclusivity?

Silver sulfadiazine has already lost the exclusivity associated with its original branded product. The reference product is no longer protected by meaningful new chemical entity exclusivity. Generic manufacturers have entered the market through abbreviated applications.

Exclusivity category	Current assessment
New chemical entity exclusivity	Expired
Original product patent protection	Historical and expired or commercially immaterial
Reference-product market exclusivity	Expired
Generic competition	Established
Biosimilar pathway	Not applicable
Formulation-specific exclusivity	Depends on any separately approved and listed product
New product opportunity	Requires new formulation, delivery system, use, or commercial advantage

FDA approval history and current labeling should be checked through Drugs@FDA and the Orange Book for the specific reference product and application number because listing status, patent records, and marketing status can change over time (FDA, 2023b; FDA, 2024).

What is the Orange Book status of silver sulfadiazine?

Silver sulfadiazine products are prescription drugs, and approved products may be listed in the FDA Orange Book according to their application and marketing status. The Orange Book is the relevant source for active ingredient, dosage form, strength, therapeutic-equivalence evaluations, and any listed patent or exclusivity information (FDA, 2024).

For commercial planning, the critical distinction is between:

• A standard 1% cream that can potentially follow an ANDA pathway.
• A product with a materially different dosage form or delivery system.
• A product with a new indication or labeling claim.
• A combination product requiring additional clinical and regulatory support.

A conventional generic cream is primarily exposed to price competition. A reformulated product may avoid direct substitution but carries higher development and approval costs.

Are there Paragraph IV challenges involving silver sulfadiazine?

Paragraph IV litigation is generally associated with listed patents that remain relevant to an ANDA applicant. Because the original silver sulfadiazine cream market is mature and genericized, the principal commercial risk is not a branded patent blockade. It is the risk that a new formulation patent, packaging patent, or delivery-system patent could be asserted against a later entrant.

For a conventional 1% cream, the likely market-entry issues are:

• Therapeutic-equivalence requirements.
• Product-specific bioequivalence or performance testing.
• Manufacturing scale-up.
• Content uniformity.
• Stability.
• State and hospital purchasing contracts.
• Supply reliability.

A Paragraph IV strategy may become relevant if a newer silver sulfadiazine product has listed patents covering a differentiated formulation. Any such analysis must be conducted against the current Orange Book patent listings and FDA application records, not against the historical Silvadene label alone.

What patent litigation affects silver sulfadiazine?

There is no widely recognized current patent litigation barrier comparable to the disputes surrounding major branded oncology, immunology, or specialty drugs. The practical litigation exposure is more likely to arise from:

• A new wound-dressing platform incorporating silver sulfadiazine.
• A drug-device combination.
• A controlled-release system.
• A formulation patent covering a narrow excipient ratio.
• Trade-secret disputes over manufacturing or particle engineering.
• Product liability claims involving sulfonamide hypersensitivity or wound-healing outcomes.

The absence of a strong legacy patent estate creates a low barrier to basic entry but also limits premium pricing for undifferentiated products.

What generic entry risks exist for silver sulfadiazine?

Generic entry risk is high because the active ingredient, strength, and cream dosage form are established. A new manufacturer can compete without creating a novel clinical category.

The main risks to a new entrant are commercial rather than patent-based:

Risk	Impact
Multiple generic suppliers	Sustained price erosion
Hospital group purchasing	Low margins and contract concentration
Reference-product substitution	Limited physician loyalty
Shortage or supply interruption	Potential upside for reliable suppliers
Raw-material variability	Drug uniformity and stability risk
Tube or jar contamination	Microbiological and quality risk
Burn-center preference for dressings	Reduced cream demand
Competing antimicrobials	Substitution risk
Sulfonamide contraindications	Limits patient population

A differentiated product should therefore target an operational problem, not merely reproduce the active ingredient.

How does silver sulfadiazine compare with competing wound products?

Silver sulfadiazine competes with topical antibiotics, modern antimicrobial dressings, and non-silver wound-care products.

Product category	Main advantage	Main limitation	Implication for silver sulfadiazine
Silver sulfadiazine cream	Familiar, inexpensive, broad topical use	Repeated application and residue	Best positioned as a low-cost antimicrobial cream
Mupirocin ointment	Strong use in selected bacterial infections	Narrower role and resistance concerns	Competes in localized superficial infection
Bacitracin or polymyxin combinations	Low-cost topical products	Allergy and limited indication scope	Competes in minor wound care
Silver-impregnated dressings	Longer wear time and dressing integration	Higher cost	Threatens hospital and burn-center use
Hydrofiber or foam dressings	Exudate management and fewer changes	Limited antimicrobial activity unless combined	Competes on workflow efficiency
Medical honey products	Wound-care positioning	Variable reimbursement and evidence base	Competes in selected chronic wounds
Non-antimicrobial advanced dressings	Moisture management and healing support	Higher acquisition cost	May replace cream when dressing performance dominates

Silver sulfadiazine retains value where cost, familiarity, and broad topical antimicrobial coverage matter. It is less competitive where clinicians prioritize fewer dressing changes, moisture management, or integrated wound-bed control.

What commercial opportunities exist for silver sulfadiazine?

The most credible opportunities are below.

Unit-dose and contamination-control packaging

Single-use sachets, foil packets, or unit-dose tubes could reduce contamination and improve nursing workflow. The opportunity is strongest in hospitals, emergency departments, long-term-care facilities, and home-health settings.

Packaging patents may be more defensible than basic formulation patents if the system provides a measurable contamination-control or dose-delivery advantage.

Large-area application systems

A metered pump, non-aerosol spray, or spreadable foam could improve application speed for large burns. Commercial value would depend on reliable dose delivery and low product loss.

Low-residue and easy-clean formulations

A cream or gel that leaves less residue could reduce dressing-change time and improve patient acceptance. Comparative usability data would be central to the product claim.

Pediatric and outpatient positioning

A formulation with improved spreadability, reduced mess, and more convenient packaging could target pediatric burn care and outpatient treatment. The product would still need appropriate safety evidence for the proposed age range and labeling.

Combination wound-care systems

Silver sulfadiazine could be paired with a dressing, applicator, barrier film, or wound-care kit. These products may create a broader commercial offering, but drug-device combination-product requirements would increase.

Supply-chain and contract-manufacturing opportunities

Because the active ingredient is mature, a reliable supplier can compete through:

• Dual-source raw materials.
• Domestic or regional manufacturing.
• Shorter lead times.
• Hospital contract supply.
• Private-label manufacturing.
• Flexible tube and unit-dose capacity.

This strategy is less dependent on patent exclusivity and more dependent on quality systems, cost control, and procurement access.

How strong is the patent estate for silver sulfadiazine?

The legacy patent estate is weak for the basic 1% cream. The strongest prospective patent positions would cover a clearly defined delivery platform or manufacturing result.

Patent subject	Expected strength
Silver sulfadiazine compound	Very weak due to age
Conventional 1% cream	Weak
Routine excipient substitution	Weak to moderate
Narrow formulation with unexpected stability or release result	Moderate
Novel foam, film, hydrogel, or dressing	Moderate to strong if technically differentiated
Combination product	Moderate, depending on claims and prior art
Manufacturing method	Moderate if it solves reproducible scale-up or uniformity problems
Packaging system	Moderate if contamination or dosing benefit is demonstrated

Patent strength will depend on claim scope, prior-art density, enablement, and clinical relevance. Formulation claims should be supported by head-to-head data rather than compositional descriptions alone.

What FDA regulatory pathway applies to a new silver sulfadiazine product?

A conventional 1% cream designed to match the reference product may be developed through an ANDA. A product with a new dosage form, novel excipient system, new route, new delivery mechanism, or new clinical claim may require a 505(b)(2) application or another FDA pathway.

The regulatory decision affects the commercial plan:

Product concept	Likely regulatory direction
Same 1% cream and equivalent performance	ANDA
Different cream base but same general dosage form	ANDA may be possible, subject to FDA requirements
Hydrogel, foam, spray, film, or dressing	Potential 505(b)(2) or combination-product pathway
New indication	505(b)(2) or supplemental application, depending on product
Device-integrated delivery system	Combination-product review may apply
Novel clinical wound-healing claim	Additional clinical evidence likely

FDA guidance on topical dermatological products emphasizes formulation, comparative performance, release, permeation, and product quality considerations. The development program should establish the relationship between excipient changes and product performance rather than rely only on chemical equivalence (FDA, 2022).

Key Takeaways

• Silver sulfadiazine is a mature, genericized topical antimicrobial with limited legacy patent value.
• The reference product is a 1% cream using a conventional water-miscible excipient base.
• A standard generic cream is exposed to intense price competition and offers limited patent differentiation.
• The most attractive commercial opportunities are low-residue creams, hydrogels, foams, sprays, unit-dose packaging, and drug-device wound-care systems.
• Excipient changes should target measurable improvements in residence time, spreadability, removal, stability, dose uniformity, or contamination control.
• A conventional equivalent cream may fit the ANDA pathway; materially different dosage forms may require a 505(b)(2) or combination-product strategy.
• Biosimilar risk does not apply because silver sulfadiazine is a small-molecule topical drug.
• The strongest new patent positions are likely to cover delivery systems, manufacturing processes, packaging, or excipient combinations with demonstrated technical effects.
• Commercial success will depend more on cost, supply reliability, hospital contracting, and workflow efficiency than on legacy exclusivity.

FAQs About Silver Sulfadiazine Excipient and Commercial Strategy

Can propylene glycol be removed from silver sulfadiazine cream?

Yes, but removal could change wetting, hydration, viscosity, drug distribution, preservation, and skin feel. The revised product would require comparative quality and performance testing.

Is a silver sulfadiazine hydrogel commercially attractive?

Potentially. A hydrogel could offer lower residue and improved application, but silver compatibility, antimicrobial activity, stability, preservation, and regulatory requirements create meaningful development work.

Can silver sulfadiazine be sold over the counter?

The approved prescription status does not automatically permit over-the-counter sale. An OTC product would require an FDA-compliant OTC monograph pathway or an approved application supporting nonprescription use.

Does silver sulfadiazine have pediatric commercial potential?

Yes. Pediatric opportunity is strongest in convenient, low-residue, unit-dose products with clear dosing and application instructions. Pediatric positioning does not remove the need to address sulfonamide hypersensitivity and age-specific safety considerations.

Which silver sulfadiazine product has the strongest commercial moat?

A conventional cream has little moat. A product combining a validated low-residue or controlled-release formulation with unit-dose packaging, reliable supply, and hospital workflow advantages would have a stronger commercial position.

References

1. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). FDA.

2. U.S. Food and Drug Administration. (2022). Topical dermatological drug products containing corticosteroids: In vitro release test studies. FDA.

3. U.S. Food and Drug Administration. (2023a). Silvadene Cream 1% prescribing information. FDA.

4. U.S. Food and Drug Administration. (2023b). Drugs@FDA: FDA-approved drugs database. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.